About 60 Mcg Darbepoetin Alfa Injection
Experience gilt-edged therapeutic results with the crowning formulation of 60 Mcg Darbepoetin Alfa Injection, offered at an unbeatable price for our clients in India. Capitalise on this affordable, excellent solution designed to manage anemia associated with CKD and chemotherapy. Encased in a single-use, latex-free glass syringe with needle guard, each 60 mcg dose delivers reliable erythropoiesis stimulation. Suitable for adults and children, administered via subcutaneous or intravenous injection. With prolonged half-life and reduced dosing frequency, this ESA formulation presents a superior patient experience.
Excellent Therapeutic Use and Advantages
The 60 Mcg Darbepoetin Alfa Injection is used to effectively treat anemia linked with chronic kidney disease and chemotherapy. Its main advantage lies in its prolonged half-life, which allows for reduced dosing frequency compared to other products. Designed for subcutaneous or intravenous injection, this crowning ESA is suitable for both adults and children under prescription guidance, providing gilt-edged results and excellent safety with latex-free packaging.
Premium Domestic Market Features and Fast Arrival
This product is widely distributed, exported, and supplied throughout India's premium domestic market. Express shipping and sample availability ensure prompt arrival at your doorstep. Compliance with essential certifications upholds safety and efficacy standards. Capitalise on our quality assurance and guaranteed shelf life of 24 months, making this sterile, odorless injection a preferred choice for healthcare professionals and patients alike.
FAQ's of 60 Mcg Darbepoetin Alfa Injection:
Q: How is the 60 Mcg Darbepoetin Alfa Injection administered?
A: It is administered subcutaneously or intravenously using the provided single-use, prefilled glass syringe. Administration should only be by or on the instruction of a healthcare provider.
Q: What are the primary indications for using this injection?
A: The injection is indicated for treating anemia associated with chronic kidney disease (CKD) and chemotherapy-induced anemia in both adults and children.
Q: When should the use of Darbepoetin Alfa Injection be avoided?
A: It should not be used in individuals with uncontrolled hypertension or hypersensitivity to darbepoetin alfa or any of its components.
Q: Where should the injection be stored before usage?
A: It must be refrigerated between 2C-8C, protected from light, and never frozen to ensure product integrity and efficacy.
Q: What process should be followed to monitor dosing safety?
A: Hemoglobin levels should be regularly checked to avoid increases above target levels, as part of the ongoing treatment plan prescribed by a healthcare professional.
Q: What benefits does this formulation offer compared to other erythropoiesis-stimulating agents?
A: The main benefit is its prolonged half-life, resulting in reduced dosing frequency and a more convenient treatment schedule for patients.